3 julio 2015
The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC), researchers. The safety profile and progression free survival were similar to phase III trial results.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/saXZVP2Cyz8/150703072607.htm
